Coya Therapeutics Inc (COYA)

$4.96 -0.02 (-0.40%)
Market Cap 103.78M
Revenue (ttm) 3.55M
Net Income (ttm) -14.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -419.15%
Debt to Equity Ratio 0.00
Volume 82,000
Avg Vol 228,144
Day's Range N/A - N/A
Shares Out 20.92M
Stochastic %K 76%
Beta 0.27
Analysts Strong Sell
Price Target $16.07

Company Profile

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase...

Industry: Biotechnology
Sector: Healthcare
Phone: 800 587 8170
Address:
5850 San Felipe St., Suite 500, Houston, United States
zampy
zampy Feb. 25 at 1:17 PM
$COYA Going thru $5 today ..60m in cash..no debt...fda Skipping a step..toooooooooooooo friggin cheap.... Shoukd be $10 plus right now....
0 · Reply
Jwa68
Jwa68 Feb. 25 at 11:39 AM
$GANX $COYA Sector Sentiment: The sector has shifted from underperformance (2021–2024) to a leadership role in early 2026, supported by strong M&A activity and regulatory tailwinds.
0 · Reply
Jwa68
Jwa68 Feb. 25 at 11:26 AM
$COYA Added 25k shares recently.
0 · Reply
zampy
zampy Feb. 25 at 12:29 AM
$COYA Buying today was institutional....Unlike the last few weeks with price sensitive..not the case today??? 1. Could it be 3m shorts just starting to cover? 2. Can it be Khalid telling his buddies it is showtime like he has before? 3. FDA decision which was rendered last week seeping into the market? 4. Could it be Sanofi...Mrk..Teva..JNJ...etc taking a position? 5. On the KOL they want to see DURABILITY after 180 days to make sure NOT an experiment? 6. Is it because we have a drug that is indeed worth billions and we should be sitting at $10? 7. IT IS NOT THE OPPENHEIMER fireside chat.....0%!!!!!! MEANINGLESS..... THOUGHTS???
2 · Reply
irf944
irf944 Feb. 24 at 8:55 PM
$COYA
0 · Reply
zampy
zampy Feb. 24 at 6:06 PM
$COYA adding sub 5...wont last
0 · Reply
Jwa68
Jwa68 Feb. 24 at 2:31 PM
$COYA 3:45 mark...neuroscience and inflammation...just saying. https://www.cnbc.com/video/2026/02/23/eli-lilly-has-already-won-the-weight-loss-drug-battle-says-mizuhos-jared-holz.html
0 · Reply
Jwa68
Jwa68 Feb. 23 at 12:26 AM
$COYA This is fortelling...LinkedIn in post by very senior executive at Dr. Reddy’s (with M&A in his title) Clearly in his own words shows DRL steong commitment to Coya and their joint drug development. Stage is clearly set...
2 · Reply
Jwa68
Jwa68 Feb. 23 at 12:14 AM
$GANX Last weeks fundamental shift by the FDA marks a changing of the tide for companies like this one and my other favorite $COYA. Pharma seeks clarity and quick time to market and revenue. They can now easily measure it with both companies drugs knowing that time to market is likely dramatically accelerated and the assets dramatically de risked. Likely to fuel a dramatic uptick in earlier stage licensing and acquisitions.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 22 at 7:58 PM
$COYA RSI: 48.97, MACD: -0.0687 Vol: 0.14, MA20: 4.75, MA50: 5.08 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Latest News on COYA
Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

Feb 10, 2026, 8:00 AM EST - 19 days ago

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

Coya Therapeutics Announces $11.1 Million Private Placement

Jan 30, 2026, 8:00 AM EST - 4 weeks ago

Coya Therapeutics Announces $11.1 Million Private Placement

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

Jan 20, 2026, 8:00 AM EST - 5 weeks ago

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients

Jan 8, 2026, 8:00 AM EST - 7 weeks ago

Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients

Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)

Jan 5, 2026, 8:00 AM EST - 7 weeks ago

Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)

Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Dec 23, 2025, 8:00 AM EST - 2 months ago

Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS

Dec 9, 2025, 8:00 AM EST - 2 months ago

Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS

Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences

Nov 25, 2025, 8:00 AM EST - 3 months ago

Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences

Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

Nov 12, 2025, 8:00 AM EST - 3 months ago

Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo

Nov 4, 2025, 8:00 AM EST - 4 months ago

Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo

Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter's Option to Purchase Additional Shares

Oct 27, 2025, 4:01 PM EDT - 4 months ago

Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter's Option to Purchase Additional Shares

Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock

Oct 24, 2025, 6:30 AM EDT - 4 months ago

Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock

Coya Therapeutics Announces Proposed Public Offering of Common Stock

Oct 23, 2025, 4:31 PM EDT - 4 months ago

Coya Therapeutics Announces Proposed Public Offering of Common Stock

Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function

Oct 7, 2025, 8:00 AM EDT - 5 months ago

Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function

Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia

Sep 29, 2025, 8:00 AM EDT - 5 months ago

Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia

Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis

Sep 22, 2025, 8:00 AM EDT - 5 months ago

Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis

Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model

Sep 16, 2025, 8:00 AM EDT - 5 months ago

Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model

Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial

Sep 4, 2025, 8:00 AM EDT - 6 months ago

Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial

PRISM MarketView Features Exclusive Q&A with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases Through Treg Therapies

Sep 3, 2025, 11:50 AM EDT - 6 months ago

PRISM MarketView Features Exclusive Q&A with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases Through Treg Therapies

Coya Therapeutics to Participate at Upcoming September Investor Conferences

Sep 3, 2025, 8:34 AM EDT - 6 months ago

Coya Therapeutics to Participate at Upcoming September Investor Conferences

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Aug 25, 2025, 8:00 AM EDT - 6 months ago

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update

Aug 12, 2025, 8:00 AM EDT - 7 months ago

Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update

Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson's Disease

Jul 24, 2025, 8:15 AM EDT - 7 months ago

Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson's Disease

Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025

Jul 22, 2025, 8:15 AM EDT - 7 months ago

Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025

Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025

Jun 18, 2025, 8:15 AM EDT - 9 months ago

Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025

Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations

Jun 2, 2025, 8:00 AM EDT - 9 months ago

Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations

Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 16, 2025, 10:53 AM EDT - 10 months ago

Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update

May 13, 2025, 8:00 AM EDT - 10 months ago

Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update

Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025

May 8, 2025, 8:15 AM EDT - 10 months ago

Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

May 8, 2025, 5:00 AM EDT - 10 months ago

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

REPL

Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release

Apr 25, 2025, 11:27 AM EDT - 11 months ago

Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

Apr 24, 2025, 8:15 AM EDT - 11 months ago

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

Apr 21, 2025, 9:51 AM EDT - 11 months ago

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025

Apr 1, 2025, 8:15 AM EDT - 11 months ago

Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025

Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program

Mar 26, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results

Mar 18, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results

Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations

Feb 25, 2025, 8:15 AM EST - 1 year ago

Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations

Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD

Feb 7, 2025, 5:17 PM EST - 1 year ago

Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD

Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must Watch

Feb 7, 2025, 1:53 PM EST - 1 year ago

Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must Watch

Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing

Feb 6, 2025, 1:30 PM EST - 1 year ago

Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing

Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development

Feb 6, 2025, 8:00 AM EST - 1 year ago

Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development

Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 8:15 AM EST - 1 year ago

Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases

Jan 21, 2025, 8:15 AM EST - 1 year ago

Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases

Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)

Dec 18, 2024, 8:15 AM EST - 1 year ago

Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)

Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference

Nov 25, 2024, 8:15 AM EST - 1 year ago

Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results

Nov 6, 2024, 8:00 AM EST - 1 year ago

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results

Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer

Nov 1, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer

Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off

Oct 31, 2024, 10:31 AM EDT - 1 year ago

Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off

Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study

Oct 29, 2024, 2:36 PM EDT - 1 year ago

Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study

Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial

Oct 29, 2024, 6:41 AM EDT - 1 year ago

Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial

zampy
zampy Feb. 25 at 1:17 PM
$COYA Going thru $5 today ..60m in cash..no debt...fda Skipping a step..toooooooooooooo friggin cheap.... Shoukd be $10 plus right now....
0 · Reply
Jwa68
Jwa68 Feb. 25 at 11:39 AM
$GANX $COYA Sector Sentiment: The sector has shifted from underperformance (2021–2024) to a leadership role in early 2026, supported by strong M&A activity and regulatory tailwinds.
0 · Reply
Jwa68
Jwa68 Feb. 25 at 11:26 AM
$COYA Added 25k shares recently.
0 · Reply
zampy
zampy Feb. 25 at 12:29 AM
$COYA Buying today was institutional....Unlike the last few weeks with price sensitive..not the case today??? 1. Could it be 3m shorts just starting to cover? 2. Can it be Khalid telling his buddies it is showtime like he has before? 3. FDA decision which was rendered last week seeping into the market? 4. Could it be Sanofi...Mrk..Teva..JNJ...etc taking a position? 5. On the KOL they want to see DURABILITY after 180 days to make sure NOT an experiment? 6. Is it because we have a drug that is indeed worth billions and we should be sitting at $10? 7. IT IS NOT THE OPPENHEIMER fireside chat.....0%!!!!!! MEANINGLESS..... THOUGHTS???
2 · Reply
irf944
irf944 Feb. 24 at 8:55 PM
$COYA
0 · Reply
zampy
zampy Feb. 24 at 6:06 PM
$COYA adding sub 5...wont last
0 · Reply
Jwa68
Jwa68 Feb. 24 at 2:31 PM
$COYA 3:45 mark...neuroscience and inflammation...just saying. https://www.cnbc.com/video/2026/02/23/eli-lilly-has-already-won-the-weight-loss-drug-battle-says-mizuhos-jared-holz.html
0 · Reply
Jwa68
Jwa68 Feb. 23 at 12:26 AM
$COYA This is fortelling...LinkedIn in post by very senior executive at Dr. Reddy’s (with M&A in his title) Clearly in his own words shows DRL steong commitment to Coya and their joint drug development. Stage is clearly set...
2 · Reply
Jwa68
Jwa68 Feb. 23 at 12:14 AM
$GANX Last weeks fundamental shift by the FDA marks a changing of the tide for companies like this one and my other favorite $COYA. Pharma seeks clarity and quick time to market and revenue. They can now easily measure it with both companies drugs knowing that time to market is likely dramatically accelerated and the assets dramatically de risked. Likely to fuel a dramatic uptick in earlier stage licensing and acquisitions.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 22 at 7:58 PM
$COYA RSI: 48.97, MACD: -0.0687 Vol: 0.14, MA20: 4.75, MA50: 5.08 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
zampy
zampy Feb. 21 at 1:54 AM
$COYA 30 cents down $15 up....
0 · Reply
Jwa68
Jwa68 Feb. 20 at 8:43 PM
$COYA https://shared.outlook.inky.com/link?domain=www.pbs.org&t=h.eJxFzdFqwzAMheFXKbme4iTNnKYw1jcZsq3UXp04WA4ujL37bMbYnfgPfPpqjuib66mxKe18FSLn3O6K2xDvYqPMNhxRWEKfrMgWEzgG9AzJEhjHhEzlLv3hvCcDqFOIQNFpMLjR-5HWDy6GprfFRVrCEwqbUAFtcHDzcmoe9T_yXuiQwk4sPpEZza20v9TqsIqhG3AgOvevo5q7TuK4oJRakSJDsyHRT1Mv-4uUYztepmmW5-pT9QsZtl_2vqLzFayjqeN_-f4BjBlbyw.MEYCIQDIukOCzSdBJ4yTfSXyESGmBqCBBaJc-X5gZ7Zzvgv7NwIhAMce2mBJkCDfz4ZaBtsGZCHlAorDhYa923vtOmMdqTUf
0 · Reply
irf944
irf944 Feb. 20 at 7:03 PM
$COYA Added. Stock making higher lows and sitting right on Parabolic, SAR.
0 · Reply
VINCE_CARTER
VINCE_CARTER Feb. 20 at 6:50 PM
$COYA or $GANX I know alot of y'all are in both. Which do you prefer and why? My initial read is $COYA has a higher ceiling/lower floor. I have had a starter position there for a few months ~$5 Any thoughts are appreciated.
2 · Reply
zampy
zampy Feb. 20 at 6:09 PM
$COYA Pretty apparent the seller is Legacy shares...No one owns the stock here and being hit wherever they see a bid..Bought 3000 more shares here its a friggin gift...
0 · Reply
zampy
zampy Feb. 20 at 12:56 PM
$GANX F.D.A. decision yesterday for R&D companies is ENORMOUS!!! 1 less step leads to far less cash burn and dilution And a lot closer to the finish line!!! Great for $COYA and $GANX This will become the hottest sector!!
1 · Reply
Jwa68
Jwa68 Feb. 20 at 3:11 AM
$COYA The human impact can't be ignored. What Coya is doing is so important. RIP Eric.
2 · Reply
Jwa68
Jwa68 Feb. 19 at 5:57 PM
$GANX $COYA Let's go! Little tailwind finally starting to develope on the heals of a 4 year biotech black swan market. Those who survived and have strong assets targeting neurodegenerative diseases, are right in the sweet spot. https://www.biopharmadive.com/news/fda-makary-prasad0one-pivotal-trial-nejm/812557/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202026-02-19%20BioPharma%20Dive%20%5Bissue:81899%5D&utm_term=BioPharma%20Dive
1 · Reply
Jwa68
Jwa68 Feb. 19 at 2:07 PM
$GANX $COYA This speaks for itself. Hard to identify two small off the radar biotechs who are targeting more of an unmet need of national interest and consequence. CNS is the sweet spot. Money flowing into the space and pharma looking for earlier stage compelling assets. Only a matter of time... FDA will drop two-study requirement for new drug approvals, aiming to speed access https://apnews.com/article/fda-drug-approval-studies-makary-prasad-a5aaa5501ae15f264bbd20d0dffa4dc4
3 · Reply
zampy
zampy Feb. 19 at 2:05 PM
$GANX Interesting that KKR owns 39.6% of Marshall Wace.....Things getting Interesting. Also both Marshall Wace and SIG bought $GANX and $COYA.......
1 · Reply
Jwa68
Jwa68 Feb. 19 at 2:03 PM
$COYA Nice listen.
0 · Reply
zampy
zampy Feb. 19 at 12:32 PM
$COYA 13 F's We are now at 39.6% institutions.....Better hands than ever before.... This will catch a bid as 58m in cash no debt..Stop the progression of 2 indications FTD the Bruce Willis disease and ALS .....unprecedented...
0 · Reply